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For  a  number  of  disease  entities,  oxidative  stress  becomes  a 
significant factor in the etiology and progression of cell dysfunction 
and injury.  Therapeutic strategies that can identify novel signal 
transduction pathways to ameliorate the toxic effects of oxidative 
stress may lead to new avenues of treatment for a spectrum of disor-
ders that include diabetes, Alzheimer’s disease, Parkinson’s disease   
and  immune  system  dysfunction.  In  this  respect,  metabotropic 
glutamate  receptors  (mGluRs)  may  offer  exciting  prospects  for 
several disorders since these receptors can limit or prevent apop-
totic cell injury as well as impact upon cellular development and 
function. Yet the role of mGluRs is complex in nature and may 
require specific mGluR modulation for a particular disease entity 
to maximize clinical efficacy and limit potential disability. Here we 
discuss the potential clinical translation of mGluRs and highlight 
the role of novel signal transduction pathways in the metabotropic 
glutamate  system  that  may  be  vital  for  the  clinical  utility  of 
mGluRs.
Oxidative Stress and Apoptotic Cell Injury
  A  number  of  mechanisms  can  account  for  the  degeneration 
of cells in the body, but the generation of cellular oxidative stress 
represents a significant component for cell loss in several diseases. 
Oxidative stress occurs as a result of the development of reactive 
oxygen species (ROS) that consist of oxygen free radicals and other 
chemical  entities.  Oxygen  consumption  in  organisms,  or  at  least 
the rate of oxygen consumption in organisms, has intrigued a host 
of investigators and may have had some of its original origins with 
the work of Pearl. Pearl proposed that increased exposure to oxygen 
through an increased metabolic rate could lead to a shortened life 
span.1 Subsequent work by multiple investigators has furthered this 
hypothesis by demonstrating that increased metabolic rates could 
be  detrimental  to  animals  in  an  elevated  oxygen  environment.2 
With current work, oxygen free radicals and mitochondrial DNA 
mutations have become associated with oxidative stress injury, aging 
mechanisms, and accumulated toxicity for an organism.3 
 Oxidative stress is a result of the release of ROS that include 
superoxide free radicals, hydrogen peroxide, singlet oxygen, nitric 
oxide,  and  peroxynitrite.4  Oxygen  free  radicals  and  mitochon-
drial  DNA  mutations  have  become  associated  with  tissue  injury, 
aging, and accumulated toxicity for an organism.5,6 Most ROS are 
produced at low levels during normal physiological conditions and 
are scavenged by endogenous antioxidant systems that include super-
oxide dismutase, glutathione peroxidase, catalase, and small molecule 
substances, such as vitamins C, E, D3
7 and nicotinamide, the amide 
form of niacin or vitamin B3.60-63
  Oxidative  stress  represents  a  significant  mechanism  for  the 
destruction of cells that can involve apoptotic cell injury.8-10 It has 
recently been shown that genes involved in the apoptotic process 
are  replicated  early  during  processes  that  involve  cell  replication 
and transcription, suggesting a much broader role for these genes 
than  originally  anticipated.11  Apoptotic  induced  oxidative  stress 
in  conjunction  with  processes  of  mitochondrial  dysfunction  can 
contribute to a variety of disease states such as diabetes, ischemia, 
general cognitive loss, Alzheimer’s disease, and trauma.12-16 Oxidative 
stress can lead to apoptosis in a variety of cell types that involve 
neurons, endothelial cells (ECs), cardiomyocytes, and smooth muscle 
cells through multiple cellular pathways.14,17-21 
 Membrane phosphatidylserine (PS) externalization is an early 
event  during  cell  apoptosis22,23  and  can  become  a  signal  for  the 
phagocytosis  of  cells.10,24,25 The  loss  of  membrane  phospholipid 
asymmetry  leads  to  the  externalization  of  membrane  PS  residues 
and  assists  microglia  to  target  cells  for  phagocytosis19,26-29  This 
process occurs with the expression of the phosphatidylserine receptor 
(PSR)  on  microglia  during  oxidative  stress,5,30  since  blockade  of 
PSR function in microglia prevents the activation of microglia.27,31 
As an example, externalization of membrane PS residues occur in 
neurons during anoxia,32-34 nitric oxide exposure,35,36 and during 
the administration of agents that induce the production of reactive 
oxygen species, such as 6-hydroxydopamine.37 Membrane PS exter-
nalization on platelets also has been associated with clot formation 
in the vascular system.38 
 The cleavage of genomic DNA into fragments39-41 is considered 
to be a later event during apoptotic injury.42 Several enzymes respon-
sible for DNA degradation have been differentiated and include the 
*Correspondence to: Kenneth Maiese, M.D.; Department of Neurology, 8C-1 UHC; 
Wayne State University School of Medicine; 4201 St. Antoine; Detroit, Michigan 
48201  USA;  Fax:  313.966.0486;  Email:  kmaiese@med.wayne.edu,  aa2088@
wayne.edu
Submitted: 08/21/08; Revised: 08/26/08; Accepted: 08/27/08
Previously published online as an Oxidative Medicine and Cellular Longevity E-publication: 
www.landesbioscience.com/journals/oximed/article/6842
Review 
Therapeutic promise and principles
Metabotropic glutamate receptors 
Kenneth Maiese,1–5,* Zhao Zhong Chong,1 Yan Chen Shang1 and Jinling Hou1
1Division of Cellular and Molecular Cerebral Ischemia;  2Departments of Neurology and Anatomy & Cell Biology; 3Barbara Ann Karmanos Cancer Institute; 4Center for Molecular 
Medicine and Genetics; 5Institute of Environmental Health Sciences; Wayne State University School of Medicine; Detroit, Michigan USA
Key words: Akt, Alzheimer’s disease, amyotrophic lateral sclerosis, apoptosis, β-catenin, erythropoietin, forkhead, Huntington’s disease, 
metabotropic, oxidative stress, Wnt
www.landesbioscience.com             Oxidative Medicine and Cellular Longevity   1Promise and principles for metabotropic receptors
2             Oxidative Medicine and Cellular Longevity   2008; Vol. 1 Issue 1
has been associated with many effector molecules including adenylate 
cyclase (AC), phospholipase C-β (PLC-β), mitogen-activated protein 
kinases (MAPKs), and phosphoinositide 3 kinase (PI 3-K).63  
G-protein-coupled  receptors  can  be  divided  into  three  major 
subfamilies based on nucleotide and amino acid sequence similarity. 
Family  A  consists  of  the  rhodopsin/adrenergic  receptors  and  is 
characterized by the presence of a restricted number of conserved 
residues (Asp-Arg-Tyr). Family B consists of peptide hormone and 
neuropeptide  receptors  that  are  characterized  by  a  large  extracel-
lular NH2 terminus containing six cysteine residues. Metabotropic 
glutamate receptors share a common molecular morphology with 
other G protein–linked receptors. The mGluRs are part of family C 
of G-protein-coupled receptors, which also includes gamma amin-
obutyric  acid  (GABA)  receptors  and  ionotropic  calcium  receptor 
transmission. Unlike the other G-protein-coupled receptors fami-
lies, mGluRs contain a long NH2 terminal chain and couple to 
G-proteins through their second intracellular loop rather than the 
third intracellular loop of the receptor.
The mGluRs also are classified into three major groups based 
on sequence homology, G-protein coupling specificity, and agonist 
selectivity.  Group  I  mGluRs  (including  mGluR1  and  mGluR5) 
couple preferentially to Gq to stimulate PLC-β. Activation of PLC-β 
results in the generation of two second messengers, inositol-1, 4, 
5-triphosphate (IP3) and diacylglycerol (DAG), to mobilize intracel-
lular calcium and activate protein kinase C (PKC). Group I mGluRs 
also can activate AC via coupling to Gs to result in an increase in 
cAMP.64 In contrast to group I mGluRs, group II mGluRs (including 
mGluR2 and 3) and group III mGluRs (including mGluR4, 6, 7, 
and 8) are negatively coupled to AC to reduce the amount of intra-
cellular cAMP. In addition, activation of group II/III can modulate 
activity of extracellular signal-regulated protein kinases (ERKs) and 
PI 3-K (Fig. 1).65 Yet, different subgroups of the mGluR system 
may employ pathways of ERKs. For example, group I mGluRs can 
increase the phosphorylation of ERK2 through PKC.66 In addition, 
ERKs may employ phosphorylation of the pro-apoptotic protein Bad 
and induction of pro-survival gene expression via the cAMP respon-
sive element-binding (CREB) protein dependent pathway to lead to 
cellular protection.67 It is not entirely evident whether the protective 
mechanisms utilized by mGluRs also involve the cellular pathways 
of the MAP-kinases, since activation of mGluRs does not alter the 
activity of either p38 or c-Jun N-terminal kinase (JNK), suggesting 
that protection by mGluRs is independent or below the level of p38 
activation.10,68
The  G-protein-coupled  receptor  family  is  the  largest  family 
of cell-surface molecules. These receptors are activated by a wide 
variety of stimuli, including neurotransmitters, peptides, hormones, 
growth  factors,  ions,  lipids  and  light. The  mGluR  system  is  one 
of the principal members in this receptor family and provides an 
important  function  as  presynaptic  auto-receptors  that  mediate 
feedback inhibition of glutamate release in a wide variety of brain 
regions. One of the mechanisms of glutamate inhibition is thought 
to  result  from  the  down-regulation  of  voltage-activated  calcium 
channels which are necessary for synaptic vesicle exocytosis.69 The 
mGluR  system  also  is  a  critical  mediator  for  the  modulation  of 
intracellular signal cascades and physiological function. Interaction 
among each G-protein subunit, such as -a, -β and -g subunits, can 
stimulate  effector  molecules  including  adenylyl/guanylyl  cyclases, 
acidic, cation independent endonuclease (DNase II), cyclophilins, 
and  the  97  kDa  magnesium-dependent  endonuclease.4,12  Three 
separate endonuclease activities are present in neurons that include 
a constitutive acidic cation-independent endonuclease, a constitu-
tive calcium/magnesium-dependent endonuclease, and an inducible 
magnesium dependent endonuclease.43,44 
  During  oxidative  stress,  mitochondrial  membrane  transition 
pore permeability also is increased,19,45-47 a significant loss of mito-
chondrial NAD+ stores occurs, and further generation of superoxide 
radicals  leads  to  cell  injury.28,48  In  addition,  mitochondria  are  a 
significant  source  of  superoxide  radicals  that  are  associated  with 
oxidative stress.12,49 Blockade of the electron transfer chain at the 
flavin  mononucleotide  group  of  complex  I  or  at  the  ubiquinone 
site of complex III results in the active generation of free radicals 
which can impair mitochondrial electron transport and enhance free 
radical production.4,30 Furthermore, mutations in the mitochondrial 
genome have been associated with the potential development of a 
host of disorders, such as hypertension, hypercholesterolemia, and 
hypomagnesemia.50,51 Reactive oxygen species also may lead to the 
induction of acidosis-induced cellular toxicity and subsequent mito-
chondrial failure.13 Disorders, such as hypoxia,52 diabetes53,54 and 
excessive free radical production44,55,56 can result in the disturbance 
of intracellular pH. 
Metabotropic Glutamate Receptors (mGluRs) Structure  
and Functional Role
  Glutamate,  an  excitatory  neurotransmitter,  plays  an  impor-
tant role during both cellular function and cellular injury in the 
mammalian central nervous system (CNS). Until the mid 1980s, the 
actions of glutamate in the brain were believed to occur through the 
activation of glutamate-gated channels termed ionotropic glutamate 
receptors. Yet, further studies provided evidence for the existence of 
another family of glutamate receptors that was directly coupled to 
GTP-binding regulatory proteins. Initial work, such as the observa-
tion of glutamate induced phospholipase C generation in neurons, 
indicated that glutamate had more complex roles that could not be 
accounted for by only N-methyl-D-aspartate (NMDA), a-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), or kainate 
receptor families.57 Subsequently, it became evident that a new class 
of  glutamate  receptors,  termed  metabotropic  glutamate  receptors 
(mGluRs), was coupled to effector systems through GTP-proteins 
(G-proteins).58-60 
 The first mGluR, now generally termed mGluR1a, was cloned 
in 1991 by a functional expression screening procedure.60,61 Since 
molecular  cloning  has  preceded  pharmacological  characterization 
in the identification of novel mGluRs, the mGluRs are numbered 
following  the  order  in  which  their  cDNAs  have  been  cloned. 
G-proteins  consist  of  heterotrimeric  proteins  that  contain  three 
subunits  termed  a,  β  and  g.  At  least  forty-six  G-proteins  have 
been identified with twenty-seven classified as Ga, five classified as 
Gβ, and fourteen classified as the Gg. A variety of heterotrimeric 
combinations can be formed that may produce a broad spectrum 
of G-protein signaling.62 Activation of G-protein-coupled receptors 
results in the dissociation of the heterotrimer of the G-protein into 
its a and βg subunits, which can then bind to a variety of effector 
molecules. A particular G-protein may be responsible for the modu-
lation of a series of signal transduction pathways. The G-protein βg Promise and principles for metabotropic receptors
www.landesbioscience.com             Oxidative Medicine and Cellular Longevity   3
transmission at excitatory synapses onto CA1 pyramidal cells.74 In 
addition, group I mGluRs have been shown to alter calcium homeo-
stasis  and  trigger  calcium-sensitive  gene  transcription  in  striatal 
neurons.75 Group II mGluRs have a significant role in the modula-
tion of GABA afferent inhibition in the ventrobasal thalamus that 
controls functions of sleep, arousal, and sensation.76 Both group I 
and II receptors may be required for the activity-dependent regu-
lation  of  ribosomes  during  auditory  function.77  High-frequency 
stimulation appears to be particularly dependent upon group I and 
group  II  metabotropic  glutamate  receptors.78  Group  III  mGluRs 
have  a  greater  role  in  motor  function  through  the  inhibition  of 
GABA  and  glutamate  transmission  in  the  substantia  nigra,  pars 
reticulata,79 and the periaqueductal grey area.80 
phosphodiesterases, phospholipases, and phosphoinositide 3-kinase 
(PI3-K)  resulting  in  the  modulation  of  other  second  messengers. 
Several second messenger systems, such as cAMP, cGMP, inositol 
(3,4,5)-trisphosphate (Ins(1,4,5)P3), arachidonic acid, phosphatidic 
acid, and calcium are active participants in these signal transduction 
cascades.70 
Electrophysiological studies of mGluRs have shown that activa-
tion of mGluRs may lead to a range of cellular changes such as the 
inhibition  of  calcium  and  potassium  currents,  mediation  of  slow 
excitatory postsynaptic potential, and the presynaptic inhibition of 
transmitter release.69,71,72 In particular, activation of group I mGluRs 
can contribute to slow-onset potentiation in the hippocampal region 
of CA1.73 Activation of postsynaptic group I mGluRs also suppresses 
Figure 1. Cytoprotection through mGluRs may require the regulation of multiple cellular pathways. G-protein βg in the mGluR system activates phospholipase 
β (PLC-β), diacylglycerol (DAG), and phosphoinositide 3 kinase (PI 3-K). These pathways lead to the activation of protein kinases A (PKA), B (Akt) and C 
(PKC) that can involve intracellular calcium (Ca2+). mGluRs can activate ERK2 through PKC. PKA can phosphorylate (p) Bad, a member of Bcl-2 protein 
family, which can prevent apoptotic cell injury. Akt provides an anti-apoptotic survival signal through the phosphorylation and inactivation of Bad and also 
interfaces with the Wnt and forkhead pathways. Wnt signaling can inhibit glycogen synthase kinase (GSK-3β). Inhibition of GSK-3β prevents phosphoryla-
tion (p) of β-catenin and leads to the accumulation of β-catenin. β-catenin subsequently translocates to the cell nucleus and contributes to the formation of 
Lef/Tcf lymphocyte enhancer factor/T cell factor (Lef/Tcf) and β-catenin complex that may cooperate with factors to target nuclear gene transcription and 
prevent cell injury. Interconnected pathways with Akt and Wnt involve the forkhead family members (FOXO), mitochondrial (Mito) membrane potential 
(DYm), cytochrome c (Cyto-c), and caspases. If left unabated, these pathways converge to lead to apoptotic cell injury.Promise and principles for metabotropic receptors
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system  development.  For  example,  redistribution  of  mGluR6  in 
rat retinal bipolar cells occurs from somatic and dendritic sites to 
restricted localization at postsynaptic sites.99 In the mouse thalamus, 
subcellular  relocalization  of  group  I  mGluRs  also  occurs  during 
postnatal development.98 In addition to redistribution of receptors, 
functional  changes  in  the  mGluR  system  also  may  occur  during 
development. The generation of second messengers, such as cAMP, 
has  been  reported  to  vary  under  mGluR  control  during  critical 
periods of ocular dominance and plasticity.103
Less information is available for the role of the mGluR system 
in  the  vascular  system,  but  new  investigations  are  beginning  to 
provide evidence for a vital function for the mGluR system in brain 
endothelial cells. Initial work has outlined the expression of mGluRs 
in cultured rat cerebrovascular ECs104 and in cardiac cells.105 Further 
studies have now demonstrated not only the expression of specific 
group I mGluRs in cerebral endothelial cells, but also the potential 
for the mGluR system to protect against apoptotic injury.26,28,106 In 
addition, mGluR1, mGluR2/3, mGluR4a, mGluR5 and mGluR7 
have  been  demonstrated  in  the  meningeal  microvasculature.107 
Interestingly, agents such as nicotine can inhibit the expression of 
mGluRs in cardiac tissue.108 More recent studies suggest that activa-
tion of mGluRs may control vascular tone.109
 mGluRs and Disorders of the Nervous and Vascular Systems
 mGluRs may be involved in diseases such as diabetes mellitus 
(DM) which is a significant health concern.110,111 Approximately 
16  million  individuals  in  the  United  States  and  more  than  165 
million individuals worldwide suffer from DM. By the year 2030, it 
is predicted that more than 360 million individuals will be afflicted 
with DM and its debilitating conditions.112 Type 2 DM represents at 
least 80% of all diabetics and is dramatically increasing in incidence 
as a result of changes in human behavior and increased body mass 
index.113 Type  1  insulin-dependent  DM  is  present  in  5–10%  of 
all diabetics,111 but is increasing in adolescent minority groups.114 
Furthermore,  the  incidence  of  undiagnosed  diabetes,  impaired 
glucose tolerance, and fluctuations in serum glucose in the young 
raises additional concerns.115 Patients with DM can develop severe 
neurological and vascular disease116,117 that can lead to an increased 
risk for cognitive decline.12,30,118 As a result, the development of 
insulin resistance and the complications of DM in the nervous and 
vascular systems are believed to be, at least in part, a result of cellular 
oxidative stress.110,111 Hyperglycemia can lead to increased produc-
tion of ROS in endothelial cells, liver and pancreatic β-cells.119-122 
Recent clinical correlates support these experimental studies to show 
that  elevated  levels  of  ceruloplasmin  are  suggestive  of  increased 
ROS.123 Furthermore, acute glucose swings in addition to chronic 
hyperglycemia can trigger oxidative stress mechanisms, illustrating 
the  importance  for  therapeutic  interventions  during  acute  and 
sustained hyperglycemic episodes.124 
  Several  studies  highlight  the  role  of  mGluRs  during  cellular 
metabolism and DM. In animal models of DM, the expression of 
mGluR1 and mGluR5 messenger RNA are significantly increased in 
all layers of the dorsal horn of the spinal cord, suggesting that mGluR 
expression and activity may be associated with the development of 
diabetic neuropathy.125 In addition, mGluRs are expressed in pancre-
atic islet cells and can impact upon the release of glucagon release. 
For example, the mGlu8 receptor is present in glucagon-secreting 
The  ubiquitous  distribution  of  glutamatergic  synapses  in  the 
nervous system offers a great potential for mGluRs to modulate global 
CNS function. In the spinal cord, Group I mGluRs can regulate slow 
excitatory synaptic transmission.81 In addition, behavioral and physi-
ological studies have demonstrated that mGluRs can regulate fast 
synaptic transmission, changes in synaptic plasticity, and the modi-
fication  of  the  calcium  currents.39,82 During memory imprinting, 
group I mGluRs which are juxtaposition to NMDA receptors can 
modulate the potentiation of NMDA receptor activity to influence 
both  long-term  potentiation  and  long-term  depression.73,83  Yet, 
multiple members of the mGluR system may be required for memory 
formation84 or memory restoration following an ischemic insult.85 
Activation  of  mGluRs  also  can  lead  to  depolarization-induced 
synapsin I phosphorylation, a process that may be involved in synaptic 
vesicle exocytosis in visceral sensory neurons.86 Furthermore, cogni-
tive impairment and psychiatric disease such as with schizophrenia 
may be tied to mGluR expression and activation.87
mGluRs Expression, Progenitor Cell Differentiation and Cell 
Development
 Metabotropic glutamate receptors are expressed throughout the 
mammalian  CNS.  In  neuronal  populations,  the  mGluR  system 
participates  in  the  processing  of  cognition,  sensory,  motor  and 
olfactory  information.  For  example,  mGluRs  are  present  in  the 
cerebral cortex,88 cerebellar neurons,89 striatal neurons and in the 
spinal  cord.90  In  the  hippocampus,  a  more  restricted  expression 
of  the  receptor  subtypes  mGluR1b,  mGluR2/3,  mGluR4a  and 
mGluR5 has been demonstrated.91 The receptor subtype mGluR4 
also has a distinct distribution in the thalamus, hypothalamus, and 
caudate nucleus.92 In the retina, mGluR6 is expressed.93 In contrast, 
mGluR3 is expressed throughout the brain with dense expression 
in neurons of the cerebral cortex, caudate-putamen, thalamus, and 
cerebellum.94 
The mGluR receptors are distributed in specific subcellular regions 
and alter their expression during development of the nervous system. 
During embryonic development, group III mGluRs may prevent the 
self-renewal of undifferentiated neocortical progenitor cells95 while 
group I mGluRs can promote neuroblast proliferation.96 Group I 
mGluRs including mGluR1a and mGluR5 predominantly exist on 
the  post-synaptic  membranes  of  the  glutamatergic  synapse  junc-
tions.97 Yet, in the initial postnatal period, mGluR1a and mGluR5 
can be found in proximal dendrites and the cell somata. With age, 
these  receptors  become  densely  distributed  in  the  distal  part  of 
dendrites to participate in synaptic function.98 Group II mGluRs 
(mGluR2/3)  are  present  primarily  in  astrocytes  surrounding  the 
neuronal somata and synapses. A less dense population of group II 
mGluRs is also located in presynaptic axon terminals. The distribu-
tion pattern of mGluR2/3 is believed to be consistently maintained 
during postnatal development.98 Of the group III mGluRs, mGluR6 
is initially distributed in both the neuronal soma and dendrites in 
rat retinal bipolar cells, but later redistributes to postsynaptic sites.99 
Presynaptic expression is more common for the mGluR7 subtypes.100 
In group III mGluRs, mGluR4, mGluR6, and mGluR8 also have 
been  identified  in  microglia  and  astrocytes.101  The  presence  of 
these  receptors  in  a  variety  of  cell  types  may  be  responsible  for 
protection  of  neuronal  cell  populations.102  Redistribution  of  the 
expression of mGluRs appears to be necessary for proper nervous Promise and principles for metabotropic receptors
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the basal ganglia. Group I mGluRs (mGluR5) can lead to an excit-
atory  drive  in  subthalamic  nucleus  neurons.151  More  specifically, 
stimulation of striatal group I mGluRs inhibits striatal projection 
neuronal  activity,  while  stimulation  of  subthalamic  metabotropic 
glutamate receptors increases subthalamic nucleus activity. 
Another  consideration  for  PD  is  the  involvement  of  group  II 
mGluRs. Group II mGluRs are presynaptically localized on subtha-
lamic  nucleus  terminals.  Activation  of  these  receptors  inhibits 
excitatory  transmission  at  subthalamic  nucleus  synapses.152  As 
a  result,  selective  agonists  of  group  II  mGluRs  can  reduce  excit-
atory  drive  through  an  indirect  pathway,  which  is  enhanced  in 
PD, and provide a different approach to the treatment of PD. For 
example,  in  a  haloperidol-induced  rat  model  of  PD,  a  selective 
agonist of group II mGluRs, LY354740 ((+)-2-aminobicyclo[3.1.0.]
hexane-2,6,-dicarboxylic  acid),  has  been  demonstrated  to  reverse 
parkinsonian muscle rigidity and catalepsy.152,153 In another model 
of  PD  through  application  of  reserpine  in  rats,  the  parkinsonian 
akinesia was relieved by injection of the group II mGluR receptor 
agonist,  (2S,2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine.154  In 
addition, group II mGluR receptor agonists may protect through 
the release of trophic factors155 or potentially modulate extracellular 
glutamate uptake.156 Taken together, agonists for group II mGluRs 
may be promising agents in the management of PD.
 Group III mGluRs also play an important role in synaptic trans-
mission in basal ganglia circuits. Of these, mGluR7 is presynaptically 
localized in the striatum, the globus pallidus, and the substantia nigra 
pars reticulata (Kosinski et al., 1999) and modulates synaptic trans-
mission through direct and indirect pathways. Activation of mGluR7 
inhibits GABA as well as glutamate transmission in the substantia 
nigra  pars  reticulata.79  As  a  result,  modulation  of  excitatory  and 
inhibitory synaptic transmission by mGluR7 may yield no alteration 
in the output of the substantia nigra pars reticulata. In contrast to 
mGluR7, mGluR4 appears to be more selectively localized in striato-
pallidal synapses and inhibits synaptic activity.157 Consequently, the 
selective agonists for mGluR4 may provide an alternate therapy for 
the treatment of PD.
 In addition to PD, other neurodegenerative disorders such as 
Alzheimer’s disease (AD) have been linked to mGluRs. AD is char-
acterized by two pathologic hallmarks that consist of extracellular 
plaques of amyloid-β peptide aggregates and intracellular neurofibril-
lary tangles composed of hyperphosphorylated microtubular protein 
tau.12,13 The β-amyloid deposition that constitutes the plaques is 
composed of a 39-42 amino acid peptide (Aβ), which is the prote-
olytic  product  of  the  amyloid  precursor  protein  (APP).13  Large 
soluble fragments (APPs) that are the result from the cleavage of APP 
within its Aβ domain are secreted into the extracellular medium. 
Overexpression of APP can accelerate Aβ secretion which can form 
insoluble  amyloid  aggregates  contributing  to  the  development  of 
AD. In AD, a downregulation of mGluR binding sites occurs.158 In 
addition, group I mGluRs are desensitized in the frontal cortex in 
AD patients and these modifications have been correlated with the 
progression of AD.159 Other work has shown that mGluR antagonists 
may control Aβ synaptic transmission.160 Interestingly, postsynaptic 
FMRP binds to and regulates the translation of amyloid precursor 
protein (APP) mRNA through metabotropic glutamate receptor acti-
vation to suggest a link between fragile X syndrome and AD.161
a-cells and intrapancreatic neurons and functions to inhibit glucagon 
release.126 Additional work has shown that mGluR3 activation can 
protect neurons from glucose related oxidative stress127 as well as 
prevent apoptotic injury in vascular cells.10
 In regards to other disorders, the modulation of the mGluR 
system has been proposed for the treatment of bipolar disease since 
these receptors may modulate signal transduction during affective 
disorders.128  Furthermore,  more  recent  work  in  animal  models 
suggests that Group III mGluRs may be beneficial for the treat-
ment of psychosis.129 For diseases such as trisomy 21, a congenital 
disorder  with  mental  impairment,  enhanced  expression  of  the 
mGluR subtype 5 has been reported.130 Furthermore, dysfunctional 
signaling in the Group I mGluR system may be responsible for other 
types of abnormal cognitive development found in disorders such as 
fragile X mental retardation caused by the lack of fragile X mental 
retardation protein (FMRP).131 
  In  progressive  disorders  such  as  amyotrophic  lateral  sclerosis 
(ALS),  the  mGluR1a  receptor  may  be  offer  endogenous  cellular 
protection, since surviving motor neurons from the spinal cord of 
ALS patients maintain mGluR1a at levels comparable to that from 
controls.132 Yet, other work indicates that mGluR inhibition may 
be required to protect neurons during ALS.133 In epilepsy, group I 
mGluR activation can lead to prolonged epileptiform discharges134 
and enhanced expression of group II and III metabotropic receptors in 
the hippocampus of patients with epilepsy has been observed,135,136 
However,  some  work  supports  a  protective  role  for  mGluRs  in 
epilepsy, since activation of group II mGluRs has been shown to 
prevent  seizures  in  experimental  animal  models.137  Furthermore, 
recent  work  illustrates  that  disruption  between  the  mGluR7a 
receptor and its PDZ-interacting protein, protein interacting with C 
kinase 1 (PICK1), can result in behavioral changes and EEG record-
ings consistent with absence epilepsy, suggesting that maintenance 
of mGluR function can protect against epileptic disorders in some 
scenarios.138 Reported abnormal expression of mGluR1 also has been 
reported in Pick’s disease.139 Modulation of synaptic and receptor 
activity by mGluRs during other chronic neuronal disorders, such as 
in Huntington’s disease, has recently been suggested to alter cellular 
susceptibility to injury.140 In particular, huntingtin protein, which is 
associated with excitotoxic death of striatal neurons, can lead to the 
desensitization of mGluR1 that may promote cell death.141 Changes 
in expression patterns of group III mGluRs also have been observed 
during inflammatory disorders, such as multiple sclerosis,101,142 and 
during acute central143 or peripheral nerve trauma.144
  mGluRs  also  appear  to  have  a  role  in  Parkinson’s  disease 
(PD). For example, mGluRs have been associated with the basal 
ganglia synaptic transmission through several mechanisms. Increased 
binding of mGluR5 in the striatum of parkinsonian primates has 
been  demonstrated  with  PET  scanning.145  Activation  of  group  I 
mGluRs  can  invoke  excitatory  postsynaptic  current  in  dopamin-
ergic  neurons,146  facilitate  dopamine  release  from  nigrostriatal 
terminals147,148 and modulate GABA release.149 In addition, group 
I  mGluR  activation  can  prevent  amphetamine-induced  rotational 
behavior in the unilateral 6-hydroxydopamine (6-OHDA) lesion rat 
model of PD.150 These results suggest that group I mGluRs agonists 
may have a therapeutic potential in PD. Yet, group I mGluRs in the 
subthalamic nucleus appear also to increase the excitation output in Promise and principles for metabotropic receptors
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in  microglia.  Activation  of  group  I  mGluRs  can  block  neuronal 
PS  exposure  and  prevented  subsequent  neuronal  cell  engulfment 
by microglia seeking neurons with PS externalization.24 However, 
other subgroups of mGluRs may invoke a different response with 
microglial activation during cell injury. For example, during ischemic 
stroke in an animal model, activation of group II mGluRs may lead 
to microglial release of tumor necrosis factor-a (TNF-a) that can be 
toxic to neurons.179
 mGluRs and Novel Signal Transduction Pathways
Protein  kinases.  Several  cellular  signal  transduction  pathways 
may  impact  upon  the  ultimate  biological  function  of  mGluRs. 
For example, the phosphatidylinositol 3-kinase (PI 3-K) pathway 
through  protein  kinase  B  (Akt)  can  determine  cytoprotection 
through  mGluRs.180  Phosphorylation  of  Akt  by  mGluRs  leads 
to  its  activation  and  protects  against  genomic  DNA  degradation 
and membrane PS exposure.24,180,181 Upregulation of Akt activity 
during  multiple  injury  paradigms,  such  as  with  matrix  detach-
ment,182  neuronal  axotomy,183  N-methyl-D-aspartate  toxicity,184 
hypoxia,185,186 β-amyloid toxicity,187,188 and oxidative stress17,19,27 
increases  cell  survival.  Akt  also  can  directly  control  microglial 
activation through the prevention of Bcl-xL degradation17 and the 
inhibition of caspase 1-, 3-, and 9-like activities.19,24,27 Activation 
of Akt by mGluRs also may contribute to new dendritic cell growth 
and protein synthesis in neurons.189 These observations are thought 
provoking since Akt is closely associated with a number of trophic 
factors such as erythropoietin (EPO).190-194 The ability of EPO to 
enhance cell survival during injury can depend upon the PI 3-K 
pathway through protein kinase B (Akt). Akt may be an essential 
component for EPO protection especially during disease processes 
such  as  diabetes,  since  inhibition  of  Akt  activity  blocks  cellular 
protection  and  anti-inflammatory  mechanisms  by  EPO.31,46,195 
EPO has been shown to employ the PI 3-K/Akt pathway in a variety 
of experimental models of injury.25,31,185,195-203 Cytoprotection in 
these models can involve transcription factor regulation,197 main-
tenance of DYm , prevention of cytochrome c release31,46,195 and 
blockade of caspase activity.31,46,185 
  Experimental  studies  have  demonstrated  that  mGluRs  can 
increase cellular survival during injury paradigms through the acti-
vation of the PI 3-K/Akt pathways26 (Fig. 1). In rat hippocampal 
neuronal  cultures,  application  of  the  group  I  mGluR  agonists 
prevent neuronal injury during oxidative stress through increased 
Akt activity.24,181 In addition, Akt activation through mGluRs may 
protect against amyloid toxicity.204 This enhancement of Akt activity 
by mGluR1 may proceed through the formation of a complex that 
includes Homer, an adaptor protein, and PI 3-K to prevent neuronal 
apoptosis.205 As a second possible protective mechanism, mGluR 
inhibition of caspase 3-like activity may serve to prevent the caspase 
3  mediated  cleavage  of  Akt  and  foster  increased  cellular  survival 
through a prolonged half-life of Akt (Fig. 1).10,68,206 Furthermore, 
regulation of Akt activity appears closely linked to memory forma-
tion  that  involves  mGluRs.207,208  Interestingly,  mGluRs,  such  as 
mGluR1a, can loss the ability to be cytoprotective and activate Akt 
during  NMDA  receptor  activation  that  may  lead  to  the  calpain-
mediated truncation of mGluR1a.209
In addition to Akt and PKC that have been previously discussed, 
protein kinase A (PKA) is another potential pathway that may offer 
 Metabotropic receptors also have been coupled to the accelera-
tion of APP processing. Activation of mGluR1 in human glioma and 
neuroblastoma cells favors the processing of APP into nonamyloido-
genic APPs resulting in the reduction of Aβ formation162 and an 
alteration in APP secretion.163 In hippocampal neurons, the release 
of APPs also is accelerated by stimulation of mGluRs, but not with 
ionotropic glutamate receptors.162 In brain cortical and hippocampal 
slices, the stimulation of group I and group II mGluRs by trans-
(1S,3R)-1-amino-1,3-cyclopentane  dicarboxylic  acid  (ACPD)  can 
increase  the  release  of  APPs. The  process  can  be  blocked  by  the 
administration  of  (±)-a-methyl-4-carboxyphenylglycine,  a  non-
selective antagonist of group I and group II mGluRs.164 
 The regulation of APP processing by mGluRs also appears to 
be dependent on the activation of protein kinase C (PKC). PKC 
consists of a family of serine-threonine kinases that are physiologi-
cally activated by a number of lipid cofactors and are considered 
to  be  important  transducers  in  several  agonist-induced  signaling 
cascades. In the PKC family, at least 12 distinct serine/threonine 
kinase isoenzymes that have important actions in transmembrane 
signal transduction pathways regulating cell proliferation, differentia-
tion, cytoskeletal functions, gene transcription, apoptosis, and drug 
resistance exist.165 Activation of PKC may be either pro-apoptotic or 
anti-apoptotic depending on the cell type.166-168 Studies have begun 
to define isoform-specific functions of PKC in the apoptotic pathway 
and the alterations of specific PKC isoforms during injury.33,167-170 
For example, PKC isoforms that appear to be anti-apoptotic include 
PKC-a,  PKC-βII,  and  PKC-e  and  the  atypical  isoforms  PKC-l 
and PKC-z.171 During free radical exposure or anoxia, activation of 
mGluRs has been shown to protect neurons through pathways that 
can  modulate  PKC.  Neuroprotection  by  the  subtypes  mGluR1a, 
mGluR2, and mGluR5 appears to be dependent on the direct modu-
lation of PKC activity (Fig. 1).167 Furthermore, PKC may be able to 
phosphorylate mGluRs and lessen activation of these receptors.172 
In regards to AD, inhibition of PKC activity can block alterations in 
secretion of APPs in response to the activation of mGluRs.162,164
 Of equal importance to the functional preservation of cells during 
neurodegenerative processes is the role of mGluRs during cellular 
inflammation. In particular, one can consider the role of microglia 
in the brain that can lead to the phagocytic removal of both neurons 
and  vascular  cells.17,19,24  During  inflammation,  microglial  cells 
require the activation of intracellular cytoprotective pathways18,25 
to proliferate and remove injured cells.29,173 Subsequently, microglia 
can form a barrier for the removal of foreign microorganisms from 
the CNS and promote tissue repair during neuronal and vascular cell 
injury.18,174 Yet, microglia also may lead to cellular damage through 
the  generation  of  reactive  oxygen  species49,175  and  through  the 
production  of  cytokines.176,177  Furthermore,  microglial  activation 
has  been  correlated  with  several  neurodegenerative  disorders  that 
include AD with the co-localization of microglia and amyloid plaque 
development.178 
 Given the impact that inflammatory cells may have upon the 
progression  or  resolution  of  degenerative  insults  throughout  the 
body, it becomes essential to consider whether mGluRs can control 
inflammatory pathways. In regards to mGluRs, activation of group 
I mGluRs can prevent neuronal membrane PS exposure and inhibit 
microglial activation by decreasing the expression of proliferating cell 
nuclear antigen (PCNA) and uptake of bromodeoxyuridine (BrdU) Promise and principles for metabotropic receptors
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can inhibit caspase 3 activity appear to offer a unique regulatory 
mechanism. For example, caspase 3 cleavage of FoxO3a can lead 
to pro-apoptotic amino-terminal (Nt) fragments that can lead to 
cell death. However, during caspase 3 inhibition, inactive phospho-
rylated FoxO3a remains intact and does not lead to apoptotic cell 
injury during oxidative stress.181,197,228 
 During periods of oxidative stress, FoxO transcription factors 
can lead to cell injury and apoptosis,190 since forkhead transcription 
factors such as FoxO1 and FoxO3a must be present for oxidative 
stress to result in apoptotic cell injury.230 In addition, FoxO3a in 
conjunction with c-Jun N-terminal kinase (JNK) has been shown 
to  modulate  an  apoptotic  ligand  activating  a  Fas-mediated  death 
pathway in cultured motoneurons,231 to lead to apoptosis through 
tumor-necrosis-factor-related  apoptosis-inducing  ligand  (TRAIL) 
and BH3-only proteins Noxa and Bim in neuroblastoma cells229 
and  to  promote  pro-apoptotic  activity  of  p53.232  These  studies 
correlate well with experimental work demonstrating that protein 
inhibition or gene knockdown of FoxO1 or FoxO3a can result in 
stroke reduction,233 enhance pancreatic β-cell or neuronal survival 
through  NAD+  precursors  during  oxidative  stress228  and  provide 
trophic factor protection in the cardiovascular system with EPO197 
and neurotrophins.234 However, some studies suggest that the loss of 
FoxO1, FoxO3a and FoxO4 protein expression may actually lead to 
an increase in free radical release that can be responsible for oxidative 
stress.235 
 In relation to mGluRs, inhibition of FoxO3a activity appears to 
be required to mediate cellular protection during oxidative stress (Fig. 
1).181 During oxidative stress in primary hippocampal neurons, free 
radical exposure can increase the phosphorylation of FoxO3a within 
6 hours, but over the course of a 12 hour period the expression of 
phosphorylated and total FoxO3a is lost, suggesting its destruction. 
In contrast, activation of the mGluR1 receptors maintains inhibitory 
phosphorylation of FoxO3a over both a 6 and 12 hour period to 
block FoxO3a activation.181 Furthermore, prevention of phospho-
rylated and total FoxO3a degradation by mGluR1 activation may 
assist with neuronal cytoprotection by inhibiting the formation of 
Nt  fragments. The  subsequent  proteolysis  of  phosphorylated  and 
total FoxO3a can lead to the generation of apoptotic amino-terminal 
(Nt) fragments.236
 The proteolytic processing of FoxO3a also is linked to the induc-
tion of caspase 3 activity. FoxO3a has been shown to be a substrate 
for caspase 3-like proteases at the consensus sequence DELD304A 
(Fig. 1).236 Blockade of caspase 3-like activity prevents the destruc-
tion  of  phosphorylated  FoxO3a  in  neurons  during  free  radical 
exposure.181 Yet, inhibition of caspase 9-like activity does not offer 
a similar level of prevention for the degradation of phosphorylated 
FoxO3a since FoxO3a has a consensus sequence specific for caspase 
3. Some protection by caspase 9 inhibition against FoxO3a degrada-
tion could be expected since caspase 3 activation is dependent upon 
initial caspase 9 activation.237 The results correlate well with other 
reports that illustrate that mGluR1 receptor activation can prevent 
caspase 3 and caspase 9 activity10,22,180 and that activation of group 
III mGluRs prevent caspase 3 activity during amyloid toxicity,238 
suggesting that the mGluR receptors are able to block the degrada-
tion of FoxO3a as a result of the inhibition of caspase activity.
 β-catenin, glycogen synthase kinase-3β and calcium pathways.  
FoxO proteins are associated with additional pathways that modulate 
control of synaptic plasticity as well as cytoprotection through the 
mGluR  system  (Fig.  1).168,210 The  mGluR  system  employs  PKA 
activation for the regulation of memory retrieval211,212 and long-
term  depression.213  In  addition,  postsynaptic  depolarization  of 
Purkinje neurons in the rat cerebellar cortex that leads to long-term 
potentiation  of  GABA  receptor  responsiveness  termed  rebound 
potentiation requires both mGluR1 and PKA.214 During paradigms 
of  cellular  injury,  activation  of  PKA  can  prevent  apoptosis  in  a 
number of cell types, including neurons, neutrophils, and smooth 
muscle cells.168,215,216 In addition, loss of PKA activity during toxic 
insults can lead to cell injury.168,217,218 Protection by PKA is believed 
to reside upstream from the inhibition of caspase 3-like activity.219 
Furthermore, PKA has been shown to phosphorylate Bad, a member 
of  Bcl-2  protein  family,  which  can  prevent  the  induction  of  cell 
injury.220 In the mGluR system, the subtype mGluR4 requires the 
activation of PKA to prevent cellular injury following acute neuro-
degenerative insults.167
 Forkhead transcription factors. Several other novel pathways that 
may determine the cytoprotective capacity of mGluRs during oxida-
tive stress are linked to Akt. For example, Akt is a central regulatory 
element for the mammalian forkhead transcription factor family that 
oversees processes that can involve cell metabolism, cell development, 
and apoptosis.117,221,222 Over one hundred forkhead genes and 19 
human subgroups that range from FOXA to FOXS are now known 
to exist since the initial discovery of the fly Drosophila melanogaster 
gene forkhead.223 In particular, members of the mammalian forkhead 
transcription factors of the O class (FoxOs), FoxO1, FoxO3, FoxO4 
and FoxO6, have emerged as important targets in the neuronal and 
vascular systems since they can modulate processes associated with 
angiogenesis, stem cell proliferation, cardiovascular injury, tumori-
genesis, and vascular cell longevity. Forkhead proteins function as 
transcription factors to either inhibit or activate target gene expres-
sion. These proteins bind to DNA through the forkhead domain 
that relies upon fourteen protein-DNA contacts. Post-translational 
modification  of  forkhead  proteins,  such  as  phosphorylation  or 
acetylation, alters the binding to DNA to prevent transcriptional 
activity. However, other mechanisms may influence DNA binding of 
forkhead proteins, such as variations in the N-terminal region of the 
DNA recognition helix, changes in electrostatic distribution, and the 
ability of forkhead proteins to be shuttled to the cell nucleus.222,224 
  Akt  can  phosphorylate  and  inactivate  FoxO1,  FoxO3a  and 
FoxO4.221,222  During  oxidative  stress,  Akt  can  prevent  cellular 
apoptosis  through  the  phosphorylation  of  FoxO  proteins.225,226 
Post-translational phosphorylation of FoxO proteins maintain FoxO 
transcription factors in the cytoplasm227 by association with 14-3-3 
proteins  and  prevent  the  transcription  of  pro-apoptotic  target 
genes.194,197 An exception in regards to the subcellular trafficking of 
FoxO proteins involves FoxO6. This FoxO protein usually resides in 
the nucleus of cells and is phosphorylated by Akt in the nucleus.222 
Activation of Akt also controls the apoptotic pathways of the caspase 
family that may offer an alternative mechanism to regulate FoxO 
proteins.4,17 The  caspases  1  and  3  have  each  been  linked  to  the 
apoptotic pathways of genomic DNA cleavage, cellular membrane 
PS exposure, and activation of inflammatory cells.31,42,46 Caspase 
pathways may be tied to the forkhead transcription factor FoxO3a 
since increased activity of FoxO3a can result in cytochrome c release 
and  caspase-induced  apoptotic  death.181,197,228,229  Pathways  that Promise and principles for metabotropic receptors
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neurofibrillary pathology248 and cardiac injury.249 GSK-3β activity 
also can influence inflammatory cell survival and activation.25,240,250 
As a result, GSK-3β is considered to be an important treatment 
strategy  for  several  degenerative  disorders.12,18,251,252  Recently, 
additional work has shown that mGluR activation blocks GSK-3β 
activity to promote translocation of β-catenin to the nucleus through 
an Akt dependent mechanism (Fig. 1).253
 Other Wnt pathways also pertain to the control of intracellular 
calcium (Ca2+) release. These involve the non-canonical or Wnt/
Ca2+  pathway  consisting  primarily  of  Wnt4,  Wnt5a  and  Wnt11 
that functions through non-β-catenin-dependent pathways and also 
include the planar cell polarity (PCP) pathway254 and the Wnt-Ca2+-
dependent pathways.254,255 In the Wnt-Ca2+-dependent pathways, 
calcium dependent kinases are activated through G-protein signaling 
that leads to elevations in intracellular Ca2+ either through cGMP or 
phospholipase activation.255-257
Interestingly  during  the  development  of  the  nervous  system, 
G-protein  signaling  with  the  mGluR  system  is  required  for  the 
modulation  of  intracellular  calcium  homeostasis.  Immature  and 
developing neurons require higher intracellular calcium concentra-
tions than their mature counterparts to facilitate neuronal survival, 
synapse formation, dendrite growth, and other cellular functions.258 
As a result, the modulation of intracellular calcium by the mGluR 
system has proven to be necessary for neuronal development, such 
in the cochlear nucleus magnocellular neurons259 and in maturing 
hippocampal neurons.39 Furthermore, group I mGluR1 facilitates 
L-type voltage-dependent calcium channels currents through PKC 
260 and group II mGluRs can control calcium flux in the suprachi-
asmatic nucleus that may oversee circadian function.261 In astrocytes, 
both group I and group II mGluRs have been associated with the 
generation of calcium oscillations.262
Modulation of intracellular calcium by the mGluR system also 
may be vital for cytoprotection (Fig. 1). For example, preservation 
of cellular energy reserves during oxidative stress is dependent upon 
the maintenance of mitochondrial integrity.263 Group I mGluRs can 
preserve mitochondrial membrane potential in endothelial cells10,26 
and neurons181,264 to prevent cell injury during oxidative stress. The 
precise mechanisms by which the mGluRs employ to preserve mito-
chondrial integrity are not clear, but may involve the modulation 
of intracellular calcium stores and intracellular pH. Reduction in 
mitochondrial intracellular calcium stores and free radical generation 
has been suggested to promote the maintenance of mitochondrial 
membrane potential and integrity.265 Activation of group I mGluRs 
can regulate the release of intracellular calcium from both Ins (1,4,5)
P3-sensitive and ryanodine-sensitive calcium stores.39 In addition, 
group  I  mGluRs  can  modulate  free  radical  signal  transduction 
cascades in both neuronal and endothelial cell populations.10,22,266 
Furthermore, intracellular acid-base levels may be involved in these 
protective mechanisms since calcium as well as pH control cellular 
endonuclease activity. For example, activation of mGluRs prevents 
cellular injury through the modulation of endonuclease activity that 
is linked to changes in intracellular pH.44
 Considerations for the Future
 As members of the broad G-protein receptor family, mGluRs 
play a diverse role in multiple processes that include cell develop-
ment,  cell  signaling,  and  cell  survival.  Effective  treatment  for  a 
cellular survival during oxidative stress. One pathway involves proteins 
derived from the Drosophila Wingless (Wg) and the mouse Int-1 genes. 
The Wnt proteins are secreted cysteine-rich glycosylated proteins that 
can control cell proliferation, differentiation, survival, and tumori-
genesis.5,6 More than eighty target genes of Wnt signaling pathways 
have been demonstrated in human, mouse, Drosophila, Xenopus and 
zebrafish. These genes are present in several cellular populations, such 
as neurons, cardiomyocytes, endothelial cells, cancer cells and pre-
adipocytes.239 At least nineteen of twenty-four Wnt genes that express 
Wnt proteins have been identified in the human.5,6,173 Wnt proteins 
are divided into functional classes based on their ability to induce 
a secondary body axis in Xenopus embryos and to activate certain 
signaling  cascades  that  consist  of  the Wnt1  class  and  the Wnt5a 
class.6,239 One Wnt pathway involves intracellular calcium release 
and is termed the non-canonical or Wnt/calcium pathway consisting 
primarily of Wnt4, Wnt5a and Wnt11. The non-canonical system 
functions  through  non-β-catenin-dependent  pathways  and  also 
includes the planar cell polarity (PCP) pathway or the Wnt-calcium-
dependent pathways.5,6,173 A second pathway controls target gene 
transcription through β-catenin, generally referred to as the canonical 
pathway that involves Wnt1, Wnt3a and Wnt8. 
 The β-catenin pathway ties FoxO proteins and Wnt signaling 
together. For example, in relation to Alzheimer’s disease, amyloid 
is toxic to cells187,240 and is associated with the phosphorylation of 
FoxO1 and FoxO3a that can be blocked with ROS scavengers.241 A 
common denominator in the pathways linked to amyloid toxicity 
involves Wnt signaling through β-catenin. β-catenin may increase 
FoxO transcriptional activity and competitively limit β-catenin inter-
action with members of the lymphoid enhancer factor/T cell factor 
family242 and β-catenin also has been demonstrated to be necessary 
for protection against amyloid toxicity in neuronal cells.240 With 
the  mGluR  system,  activation  of  group  I  mGluRs  can  modulate 
the phosphorylation of β-catenin and its intracellular translocation 
from the cytoplasm to the cell nucleus (Fig. 1). During oxidative 
stress, phosphorylation of β-catenin is increased that can lead to its 
degradation and subsequent cell injury, but group I mGluR activa-
tion blocks phosphorylation of β-catenin within 6 hours following 
free radical exposure.181 The blockade of β-catenin phosphorylation 
is associated with its translocation from the cytoplasm to the nucleus 
to allow it to assist with known cytoprotective pathways. In addition, 
the ability of mGluR activation to control the phosphorylation and 
activity of β-catenin has been shown to be dependent upon Akt1, 
since gene silencing of Akt1 expression leads to phosphorylation of 
β-catenin during oxidative stress.181 
 Glycogen synthase kinase-3β (GSK-3β) also plays a role in these 
pathways, since Wnt binds to its receptors and the co-receptor low-
density lipoprotein receptor-related protein 5/6 (LRP-5/6) to inhibit 
GSK-3β.  Pathways  that  block  GSK-3β  activity  such  as  through 
Wnt  appear  to  be  critical  for  neuronal  protection.  For  example, 
the neuroprotective attributes of Wnt1 against β-amyloid toxicity 
are  lost  during  gene  silencing  of Wnt1  protein  expression.  More 
importantly, Wnt 1 protection is dependent upon Akt activity and 
the inhibition of GSK-3β with the cellular translocation β-catenin 
to the nucleus 240. Modulation of GSK-3β activity also can regu-
late progenitor cell proliferation and differentiation,243,244 promote 
midbrain  differentiation,245  control  cardiac  hypertrophy246,247 
and  increase  cell  survival  during  oxidative  stress,  such  as  during Promise and principles for metabotropic receptors
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ing the corpses. Curr Opin Neurobiol 2005; 15:101-7.
  30.  Li F, Chong ZZ, Maiese K. Cell Life Versus Cell Longevity: The Mysteries Surrounding the 
NAD(+) Precursor Nicotinamide. Curr Med Chem 2006; 13:883-95.
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protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br 
J Pharmacol 2003; 138:1107-18.
  32.  Maiese K. The dynamics of cellular injury: transformation into neuronal and vascular pro-
tection. Histol Histopathol 2001; 16:633-44.
  33.  Maiese K, Boccone L. Neuroprotection by peptide growth factors against anoxia and nitric 
oxide toxicity requires modulation of protein kinase C. J Cereb Blood Flow Metab 1995; 
15:440-9.
  34.  Vincent AM, Maiese K. Direct temporal analysis of apoptosis induction in living adherent 
neurons. J Histochem Cytochem 1999; 47:661-72.
number  of  disease  entities  such  as  amyotrophic  lateral  sclerosis, 
psychiatric disease, Parkinson’s disease, and Alzheimer’s disease may 
ultimately rely upon mGluR modulation and targeting novel signal 
transduction pathways of metabotropic receptors during oxidative 
stress. In particular, pathways tied to Akt, forkhead transcription 
factors, β-catenin, and intracellular calcium release may prove to be 
vital for the development of new therapeutic strategies.
 Yet, the role of the mGluR activation during cell injury is not 
always clear and can differ among cell systems. In models of demy-
elinating disease, only activation of specific mGluRs has the capacity 
to  protect  oligodendrocyte  progenitor  cells.267  mGluRs  also  can 
have adverse consequences or ineffective results.268 In rat cerebellar 
granule cells and mouse cortical neurons, trophic deprivation can 
result in increased mGluR1 expression that is correlated with even-
tual cell death.269 In other scenarios, activation of the mGluR system 
may potentiate activity of the capsaicin receptor and contribute to 
hyperalgesia.270  However,  downregulation  of  the  mGluR  system 
has  been  suggested  to  lead  to  the  generation  of  post-injury  pain 
following spinal cord injury during both pharmacological271 and in 
knockdown studies.272 
 Some studies also suggest that antagonism of mGluRs may be 
beneficial. For example, inhibition of mGluR activity during the 
progression  of  a  toxic  insult  in  some  experimental  models  may 
subsequently improve neuronal survival.273,274 Acute versus chronic 
application  of  mGluR  antagonists  also  may  generate  different 
therapeutic efficacy. In a rat model of PD, it is chronic rather than 
acute treatment with a mGluR5 antagonist that can reverse akinetic 
deficits.275 Furthermore, changes in the cellular environment, such 
as decreased intracellular calcium release, may allow antagonism of 
the mGluR system to exert cytoprotection.39 In addition, the nature 
and extent of the cellular injury may determine whether activation 
or inhibition of the mGluR system is ultimately required for cellular 
protection. Since the role mGluRs play in the body is not straight-
forward,  future  investigations  are  necessary  to  further  define  the 
unique signal transduction pathways controlled by the metabotropic 
system for the effective translation of mGluRs into new therapeutic 
avenues.
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